Shanghai Haoyuan Chemexpress Co., Ltd.
Country: 
China (Mainland)
Business Type: Trading Company
This is the LookChem platform customer service phone number. The supplier hasn't provided their contact information yet. If you need assistance, please reach out to us!
According to Beacon H1 2024 ADC landscape review report[1], Since 2023, the ADC landscape grew by 21% in H1 2024, and keeping track of this landscape has never been more crucial. Topoisomerase I inhibitors have dominated the drug development market since 2023. The same trend has also been seen in newly-added drugs in H1 2024, topoisomerase I inhibitors account for 56% of the new drugs with disclosed payload, followed by tubulin inhibitors (27%). MMAE and Camptothecin are the two most common payloads used in new tubulin inhibitors and topoisomerase I inhibitors, respectively.
Source:https://beacon-intelligence.com/infographic/h1-2024-adc-landscape-review/ [1]
ChemExpress leads the field for ADC Payload-Linker and ADC conjugation. The following advantages empower us to provide better services to our clients in the ADC field, including:
• Over 80 payloads and 400 linkers in stock, 1000+ linker syntheses experience.
• 12 ADC payloads and related intermediates registered with the FDA DMF, including widely used payloads such as MMAE, Vc-MMAE, Exatecan, Eribulin, and morere.
• Supported clients with 5 projects in the preparation for the BLA submission for the past 12 months.
• 800+ existing ADC clients
• Over 10 years of experience
• Over 230 experienced ADC experts
• US FDA Inspection Concludes With Zero Observations
For more information,please download our ADC Payload-Linker Compounds Patent Analysis Report
You may also be interested in:
Exploring Out-Licensing Deals for Innovative ADC Drugs from China
|
DMF Filed ADC Small Molecule Products
|
| Shanghai Haoyuan ChemExpress Co., Ltd. | ||||
|
||||
| A: No. 3 Building, No. 1999, Zhangheng Road, Pudong New Area, Shanghai, P.R.China | ||||
| www.chemexpress.com |
